Menu Back toSession 5 Track 3: ICH Q14 Regulatory Perspective and the Impact on Process Analytical Technology

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 5 Track 3: ICH Q14 Regulatory Perspective and the Impact on Process Analytical Technology

Session Chair(s)

Claus  Rentel, PhD

Claus Rentel, PhD

  • Vice President, Analytical Development and Quality Control
  • Ionis Pharmaceuticals, Inc., United States
A new quality guideline, ICHQ14, on analytical procedure development is being developed. The intent of this guideline is to harmonize scientific approaches of analytical procedure development in both traditional and enhanced approaches. Thus, resulting in improved regulatory communication between industry and regulators by facilitating efficient and science-based change management. The session will include presentations from a member of the working group as well as industry experience implementing PAT for an oligonucleotide therapeutic. The presentations will be followed by a panel discussion.
Learning Objective :
  • Understand concepts of an enhanced approach to analytical method development and Quality by Design (QbD) principles like Risk Assessment, Design Space, and Control Strategy
  • Introduce ICH Q14 principles to analytical method validation
  • Learn about applications of PAT and the use of multivariate models in oligonucleotide manufacturing
  • Understand regulatory acceptance of strategies differing from traditional analytical method validations


Daniel  Hill, MBA


Daniel Hill, MBA

  • Associate Director Digital Development and Analytics
  • Biogen, United States
Nina S. Cauchon, PhD, RAC


Nina S. Cauchon, PhD, RAC

  • Director Regulatory Affairs CMC
  • Amgen, United States
Bryan  Castle, PhD


Bryan Castle, PhD

  • Executive Director, Synthetic Molecule Design & Development
  • Eli Lilly and Company, United States
Bogdan  Kurtyka, PhD


Bogdan Kurtyka, PhD

  • Senior Process Quality Assessor
  • FDA, United States
René  Thürmer, PhD


René Thürmer, PhD

  • Deputy Head of the Unit Pharmaceutical Biotechnology BfArM
  • Federal Institute for Drugs and Medical Devices, Germany